SHANGHAI, Oct. 11, 2024 (GLOBE NEWSWIRE) -- EpimAb Biotherapeutics, a clinical stage biotechnology company specializing in the development of bispecific antibodies and T-cell engagers, is pleased to announce the company will be presenting two poster presentations at the upcoming 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC 2024) taking place in Houston, Texas, from November 6-10, 2024, at the George R. Brown Convention Center.
The posters will feature: 1) preclinical results for a novel cMet x EGFR bispecific antibody-drug conjugate (ADC) and 2) development and preclinical data for an innovative NK cell engager platform. Details for the presentations are as follows: